High rate of complete remission and upgraded response with weekly maintenance bortezomib post single autologous peripheral stem cell transplant in patients with multiple myeloma. Results of a phase II prospective study

被引：0
|
作者：
Sahebi, F. [1 ]
Krishnan, A. [1 ]
Farol, L. [1 ]
Cai, J. -L. [1 ]
Somlo, G. [1 ]
Popplewell, L. [1 ]
Parker, P. [1 ]
Spielberger, R. [1 ]
Kogut, N. [1 ]
Karanes, C. [1 ]
Ruel, C. [1 ]
Frankel, P. [1 ]
Reburiano, E. [1 ]
Duarte, L. [1 ]
O'Donnell, L. [1 ]
Forman, S. [1 ]
机构：
[1] City Hope Med Ctr, Duarte, CA USA
来源：
BONE MARROW TRANSPLANTATION | 2011年 / 46卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
引用
收藏
页码：S39 / S39
页数：1
相关论文
共 50 条
  • [11] A Phase II Study of Sequential Velcade/Thalidomide/Dexamethasone (VTD) as Maintenance Therapy Post Single Autologous Peripheral Stem Cell (PSCT) in Patients with Multiple Myeloma
    Sahebi, Firoozeh
    Krishnan, Amrita
    Somlo, George
    Popplewell, Leslie
    Parker, P.
    Cai, Ji-Lian
    Farol, Len
    Spielberger, Ricardo
    Kogut, Neil Martin
    Karanes, Chatchada
    Ruel, Christopher
    Frankel, Paul
    Arceo, Fermin
    Duarte, Lupe
    O'Donnell, Margaret
    Forman, Stephen J.
    BLOOD, 2009, 114 (22) : 1321 - 1322
  • [12] Tandem Autologous Stem Cell Transplantation for Multiple Myeloma Patients Based on Response to Their First Transplant-A Prospective Phase II Study
    Byrne, Michael
    Salmasinia, Donya
    Leather, Helen
    Cogle, Christopher R.
    Davis, Amy
    Hsu, Jack W.
    Wiggins, Laura
    Chang, Myron N.
    An, Qi
    Wingard, John R.
    Moreb, Jan S.
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2014, 8 : 101 - 105
  • [13] Maintenance thalidomide following single cycle autologous peripheral blood stem cell transplant in patients with multiple myeloma
    F Sahebi
    R Spielberger
    N M Kogut
    H Fung
    P M Falk
    P Parker
    A Krishnan
    R Rodriguez
    R Nakamura
    A Nademanee
    L Popplewell
    P Frankel
    C Ruel
    R Tin
    P Ilieva
    S J Forman
    G Somlo
    Bone Marrow Transplantation, 2006, 37 : 825 - 829
  • [14] Maintenance thalidomide following single cycle autologous peripheral blood stem cell transplant in patients with multiple myeloma
    Sahebi, F
    Spielberger, R
    Kogut, NM
    Fung, H
    Falk, PM
    Parker, P
    Krishnan, A
    Rodriguez, R
    Nakamura, R
    Nademanee, A
    Popplewell, L
    Frankel, P
    Ruel, C
    Tin, R
    Ilieva, P
    Forman, SJ
    Somlo, G
    BONE MARROW TRANSPLANTATION, 2006, 37 (09) : 825 - 829
  • [15] Lenalidomide: Based maintenance after autologous hematopoietic stem cell transplant for patients with high-risk multiple myeloma.
    Pasvolsky, Oren
    Milton, Denai R.
    Rauf, Mikael
    Tanner, Mark R.
    Bashir, Qaiser
    Srour, Samer Ali
    Saini, Neeraj
    Ramdial, Jeremy L.
    Nieto, Yago
    Lee, Hans C.
    Patel, Krina K.
    Kebriaei, Partow
    Thomas, Sheeba K.
    Weber, Donna M.
    Orlowski, Robert Z.
    Shpall, Elizabeth J.
    Champlin, Richard E.
    Qazilbash, Muzaffar H.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [16] Combination Melphalan and Bortezomib Conditioning with Autologous Hematopoietic Stem Cell Support in Patients with Advanced Multiple Myeloma. A Phase I/II Study.
    Rowley, Scott D.
    Siegel, David
    Donato, Michele L.
    Pecora, Andrew L.
    Feldman, Tatyana
    Goldberg, Stuart
    Goy, Andre
    Masood, Aisha
    BLOOD, 2009, 114 (22) : 499 - 499
  • [17] Sequential Bortezomib, Dexamethasone, and Thalidomide Maintenance Therapy after Single Autologous Peripheral Stem Cell Transplantation in Patients with Multiple Myeloma
    Sahebi, Firoozeh
    Frankel, Paul H.
    Farol, Len
    Krishnan, Amrita Y.
    Cai, Ji-lian
    Somlo, George
    Thomas, Sandra H.
    Reburiano, Eunicia
    Popplewell, Leslie L.
    Parker, Pablo M.
    Spielberger, Ricardo T.
    Karanes, Chatchada
    Htut, Myo
    Ruel, Christopher
    Duarte, Lupe
    Murata-Collins, Joyce L.
    Forman, Stephen J.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2012, 18 (03) : 486 - 492
  • [18] Interim analysis of a phase II trial of bortezomib in patients with multiple myeloma who failed to achieve a complete response to autologous peripheral blood stem cell transplantation.
    Rifkin, RM
    Beveridge, RA
    Brunvand, MW
    Spitzer, G
    Kristi, BA
    Rauch, MA
    Zhan, F
    Asmar, L
    BLOOD, 2005, 106 (11) : 377B - 378B
  • [19] Phase II Study of the Combination of Ixazomib with Lenalidomide As Maintenance Therapy Following Autologous Stem Cell Transplant in Patients with Multiple Myeloma
    Shah, Jatin J.
    Feng, Lei
    Weber, Donna
    Thomas, Sheeba K.
    Wang, Michael
    Turturro, Francesco
    Qazilbash, Muzaffar H.
    Shah, Nina
    Bashir, Qaiser
    Popat, Uday R.
    Manasanch, Elisabet E.
    Munoz, Silvia C.
    Landry, Ashley
    Mendoza, Kathleen
    Nieto, Yago
    Champlin, Richard E.
    Orlowski, Robert Z.
    BLOOD, 2015, 126 (23)
  • [20] Update on a Phase II Study of Ixazomib with Lenalidomide As Maintenance Therapy Following Autologous Stem Cell Transplant in Patients with Multiple Myeloma
    Patel, Krina K.
    Shah, Jatin J.
    Feng, Lei
    Lee, Hans C.
    Manasanch, Elisabet E.
    Thomas, Sheeba K.
    Weber, Donna M.
    Munoz, Silvia C.
    Morphey, Ashley
    Bashir, Qaiser
    Qazilbash, Muzaffar H.
    Orlowski, Robert Z.
    BLOOD, 2017, 130
12345